Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line

British Journal of Cancer

Volumn 76, Issue 3, 1997, Pages 312-317

  Datta, S N ^a,b   Allman, R ^b   Loh, C ^a   Mason, M ^b   Matthews, P N ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

5 Aminolaevulinic acid; Bladder; Drug resistance; Mitomycin C; Neoplasm; Photochemotherapy

Indexed keywords

AMINOLEVULINIC ACID; MITOMYCIN C; PHOTOSENSITIZING AGENT;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 0030742212     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.384     Document Type: Article

References (34)

1. Baas P, Michielsen C, Oppelaar H, van Zandwijk N and Stewart FA (1994) Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model. Int J Cancer 56: 880-885
2. Baas P, van Geel IPJ, Oppelaar H, Meyer M, Beynen JH, van Zandwijk N and Stewart FA (1996) Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br J Cancer 73: 945-951
3. Bachur NR, Gordon SL and Gee MV (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745-1750
4. Bachur NR, Gordon SL, Gee MV and Kon H (1979) NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 76: 954-957
5. Battle AMC (1993) Porphyrins, porphyrias, caneer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B Biol 20: 5-22
6. Bugelski PJ, Porter CW and Dougherty TJ (1981) Autoradiographic distribution of hematoporphyrin derivative in normal and tumour tissue of the mouse. Cancer Res 41: 4606-4612
7. Chaudhuri K, Keck RW and Selman S (1987) Morphological changes of tumor microvasculature following hematoporphyrin derivative sensitised photodynamic therapy. Photochem Photobiol 46: 823-827
8. Coyle T, Levante S, Shetler M and Winfield J (1994) In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neuro-Oncol 19: 23-25
9. Dougherty TJ (1988) Photodynamic therapy. In Medical Radiology - Innovations in Radiation Oncology, Withers HR and Peters LJ (eds), pp. 175-188. Springer: Berlin
10. Dougherty TJ, Cooper MT and Mang TS (1990) Cutaneous phototoxic occurrences in patients receiving Photofrin®. Lasers Surg Med 10: 485-488
11. Harrison GSM, Green DF, Newling DWW, Richards B, Robinson MRG and Smith PH (1983). A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Br J Urol 55: 1676-1679
12. Harty JI, Amin M, Wiemann TJ, Tseng MT, Ackerman D and Broghamer W (1989) Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Urol 141: 1341-1346
13. Hetherington JW, Newling DWW, Robinson MRG, Smith PH, Adib RS and Whelan P (1987) Intravesical mitomycin C for the treatment of recent superficial bladder tumours. Br J Urol 59: 239-241
14. Kennedy JC and Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitiser for photodynamic therapy. J Photochem Photobiol B Biol 14(4): 275-292
15. Kennedy JC and Pottier RH (1994) Using δ-aminolevulinic acid in cancer therapy. In Porphyric Pesticides: Chemistry, Toxicology and Pharmaceutical Applications, Duke SO and Rebeiz CA (eds), ACS Symposium Series No. 559, pp. 291-301. American Chemical Society: Washington
16. Kriegmair M, Baumgartner R, Lumper W, Waidelich R and Hofstetter A (1996) Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 77: 667-671
17. Lemoli RM, Igarashi T, Knizewski M, Acaba L, Richter A, Jain A, Mitchell D, Levy J and Gulati SC (1993) Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells. Blood 81: 793-800
18. Loh CS, MacRobert AJ, Bedwell J, Regula J, Krasner N and Bown SG (1993) Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br J Cancer 68: 41-51
19. Lyer VN and Szybalski WA (1963) A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci USA 50: 355-362
20. Lyer VN and Szybalski WA (1964) Mitomycin and porfiromycin. Chemical mechanism of activation and cross-linking of DNA. Science 11: 55-58
21. Ma LW, Steen HB, Moan J, Berg K, Peng Q, Saether H and Rimington C (1992a) Cytotoxicity and cytokinetic effects of mitomycin-C and/or photochemotherapy in a human colon adenocarcinoma cell line. Int J Biochem 24: 1807-1813
22. Ma LW, Moan J, Steen HB, Berg K and Peng Q (1992b). Effect of mitomycin C on the uptake of photofrin II in a human adenocarcinoma cell line. Cancer Lett 64: 155-162
23. Ma LW, Moan J, Berg K, Peng Q and Steen HB (1993) Potentiation of photodynamic therapy by mitomycin C in cultured human colon adenocarcinoma cells. Radiat Res 134: 22-28
24. MacRobert AJ, Bown SG and Phillips D (1989) What are the ideal photoproperties for a sensitizer? In Photosensitizing Compounds: their Chemistry, Biology and Clinical Use, pp. 4-16, Wiley: Chichester
25. Moan J, Pettersen EO and Christensen T (1979) The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. Br J Cancer 39: 398-407
26. Nelson JS, Liaw LH and Berns MW (1987) Tumor destruction in photodynamic therapy. Photochem Photobiol 46: 829-835
27. Ross DD, Joneckis CC, Ordóñez JV, Sisk AM, Wu RK, Hamburger AW and Nora RE (1989) Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res 49: 3776-3782
28. Rossi FM, Campbell DL, Pottier RH, Kennedy JC and Gudgin Dickson EF (1996) In vitro studies on the potential use of 5-aminolevulinic acid-mediated photodynamic therapy for gynaecological tumours. Br J Cancer 74: 881-887
29. Riesenberg R, Fuchs C and Kriegmair M (1996) Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro (1996). Eur J Cancer 32A: 328-334
30. Selman SH, Kreimar-Birnbaum M, Klaunig JE, Goldblatt PJ, Keck RW and Britton SL (1984) Blood flow in transplantable bladder tumours treated with haematoporphyrin derivative and light. Cancer Res 44: 1924-1927
31. Sommerville JJF, Newling DWW, Richards B, Robinson MRG and Smith PH (1985) Mitomycin C in superficial bladder cancer: 24 week follow-up. Br J Urol 57: 586-589
32. Star WM, Marijnissen HPA, van den Berg-Blok AE, Versteeg JA, Franken KA and Reinhold HS (1986) Destruction of rat mammary tumour and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 46: 2532-2540
33. Tolley DA, Hargreave TB, Smith PH, Williams JL, Grigor KM, Parkar MK, Freedman LS and Uscinska BM (1988) Effect of mitomycin C on the recurrence of newly diagnosed superficial bladder cancer: An interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Centre Working Party). Br Med J 296: 1759-1761
34. Xu BH, Gupta V and Singh SV (1994) Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer 58: 686-692